Sara Rasta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sara Rasta has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Hossein Mardanparvar
Department of Nursing, Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
3 shared publications - Jalal Rezaei
Department of Critical Care Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Meysam Arbuzia
Department of Nursing, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2 shared publications - Sara Ghaseminejad Kermani
Department of Emergency Medicine, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Ali Rahnama Sisakht
General Medicine, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publication - Alireza Amanollahi
Trauma and Injury Research Center Iran University of Medical Sciences Tehran Iran
1 shared publication
Latest Publications
- Open Access
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38256
Role of lipoprotein (a) in kidney diseases; a review of recent data
Lipoprotein (a) is a type of lipoprotein that consists of a cholesterol-rich low-density lipoprotein particle bound to a unique protein called apolipoprotein (a). A strengthened risk of vascular diseases, such as stroke and coronary artery disease is accompanied by elevated levels of this protein. However, recent research has also highlighted the potential role of lipoprotein (a) in kidney-related conditions. Lp (a) appears to play a significant role in kidney diseases. An increased risk of kidney disease development and progression, diabetic nephropathy and renal artery stenosis, and renal transplant dysfunction accompanies high plasma values of Lp (a).
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38256
Open AccessRole of lipoprotein (a) in kidney diseases; a review of recent data
Lipoprotein (a) is a type of lipoprotein that consists of a cholesterol-rich low-density lipoprotein particle bound to a unique protein called apolipoprotein (a). A strengthened risk of vascular diseases, such as stroke and coronary artery disease is accompanied by elevated levels of this protein. However, recent research has also highlighted the potential role of lipoprotein (a) in kidney-related conditions. Lp (a) appears to play a significant role in kidney diseases. An increased risk of kidney disease development and progression, diabetic nephropathy and renal artery stenosis, and renal transplant dysfunction accompanies high plasma values of Lp (a).
- Open Access
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38251
Limb amputation following sodium-glucose cotransporter type 2 inhibitor therapy
This review article examines the association between sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and the risk of limb amputation, particularly in patients with type 2 diabetes mellitus. This review aims to provide a comprehensive understanding of the risks associated with SGLT2i therapy and to inform future research directions in this area. While SGLT2i medications, such as canagliflozin, are recognized for their cardiovascular and renal benefits, emerging evidence suggests a potential increase in the risk of lower limb amputations (LLAs) among users compared to non-users of SGLT2i. This review synthesizes findings from various studies that report a slightly elevated risk of amputation linked to SGLT2i therapy, with mechanisms proposed including diuretic-induced hypovolemia and the partial inhibition of sodium-glucose cotransporter 1. Factors such as pre-existing peripheral artery disease (PAD), sensory neuropathy, and poor foot health are identified as significant risk enhancers for lower limb amputations in this patient population. In conclusion, patients with these conditions are at increased risk of limb ischemia and subsequent amputation, and the administration of SGLT2 inhibitors may potentially further increase this risk.
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38251
Open AccessLimb amputation following sodium-glucose cotransporter type 2 inhibitor therapy
This review article examines the association between sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and the risk of limb amputation, particularly in patients with type 2 diabetes mellitus. This review aims to provide a comprehensive understanding of the risks associated with SGLT2i therapy and to inform future research directions in this area. While SGLT2i medications, such as canagliflozin, are recognized for their cardiovascular and renal benefits, emerging evidence suggests a potential increase in the risk of lower limb amputations (LLAs) among users compared to non-users of SGLT2i. This review synthesizes findings from various studies that report a slightly elevated risk of amputation linked to SGLT2i therapy, with mechanisms proposed including diuretic-induced hypovolemia and the partial inhibition of sodium-glucose cotransporter 1. Factors such as pre-existing peripheral artery disease (PAD), sensory neuropathy, and poor foot health are identified as significant risk enhancers for lower limb amputations in this patient population. In conclusion, patients with these conditions are at increased risk of limb ischemia and subsequent amputation, and the administration of SGLT2 inhibitors may potentially further increase this risk.
- Open Access
- 2 November 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (1) , e12712
The effect of body mass index on estimated glomerular filtration rate in patients with IgA nephropathy; a systematic review and meta-analysis of the cohort studies
Introduction: The study is motivated by the growing concern surrounding chronic kidney disease worldwide and the need for early identification and effective management to slow or prevent kidney disease progression. To achieve this goal, we evaluated the correlation between body mass index (BMI) and estimated glomerular filtration rate (eGFR) in patients with IgA nephropathy through a systematic review and meta-analysis. Materials and Methods: The data were acquired after conducting a comprehensive exploration of the international databases of PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine until June 2024. The study heterogeneity was evaluated utilizing the I2 index. The data were scrutinized employing STATA 14, and a P value < 0.05 was considered significant. Results: Seven studies with a sample size of 1354 normal BMI people and 1020 obese or overweight patients were included in this meta-analysis. Based on the findings of the weighted mean difference (WMD), individuals who are overweight or obese had a lower eGFR (WMD = -7.34 [CI; -9.62, -5.05], P<0.001). Conclusion: The results demonstrated that the eGFR was significantly lower in obese or overweight people compared to individuals with normal BMI; therefore, we conclude that being overweight or obese may hurt kidney function. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023417633) and Research Registry (UIN: reviewregistry1665) websites.
- 2 November 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (1) , e12712
Open AccessThe effect of body mass index on estimated glomerular filtration rate in patients with IgA nephropathy; a systematic review and meta-analysis of the cohort studies
Introduction: The study is motivated by the growing concern surrounding chronic kidney disease worldwide and the need for early identification and effective management to slow or prevent kidney disease progression. To achieve this goal, we evaluated the correlation between body mass index (BMI) and estimated glomerular filtration rate (eGFR) in patients with IgA nephropathy through a systematic review and meta-analysis. Materials and Methods: The data were acquired after conducting a comprehensive exploration of the international databases of PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine until June 2024. The study heterogeneity was evaluated utilizing the I2 index. The data were scrutinized employing STATA 14, and a P value < 0.05 was considered significant. Results: Seven studies with a sample size of 1354 normal BMI people and 1020 obese or overweight patients were included in this meta-analysis. Based on the findings of the weighted mean difference (WMD), individuals who are overweight or obese had a lower eGFR (WMD = -7.34 [CI; -9.62, -5.05], P<0.001). Conclusion: The results demonstrated that the eGFR was significantly lower in obese or overweight people compared to individuals with normal BMI; therefore, we conclude that being overweight or obese may hurt kidney function. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023417633) and Research Registry (UIN: reviewregistry1665) websites.
- Open Access
- 10 April 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
The effects of atorvastatin on contrast-induced acute kidney injury; a systematic review and meta-analysis on clinical trials
Introduction: Contrast-induced acute kidney injury (CI-AKI) is a major acute renal failure that can be prevented by atorvastatin administration. This study aims to evaluate the association between atorvastatin use and CI-AKI incidence using a systematic review and meta-analysis approach. Materials and Methods: Several international databases, including Cochrane, Web of Science, Scopus, ProQuest, PubMed, and the Google Scholar search engine, were queried in this study. STATA 14 software was conducted to analyze the data. In this study, standardized mean difference (SMD) index was conducted to investigate the relationship between atorvastatin and serum creatinine level. Results: Twelve clinical trials with a total sample size of 3299 were retrieved. The effect of atorvastatin on serum creatinine levels indicated a SMD of -2.26 (95% CI: -2.53, -1.98) at a dose of 20 mg/kg, -0.76 (95% CI: -1.47, -0.05) at a dose of 40 mg/kg, -2.69 (95% CI: -2.96, -2.42) at a dose of 60 mg/ kg, and -0.03 (95% CI: -0.14, 0.09) at a dose of 80 mg/kg. The effect of atorvastatin use on serum creatinine levels achieved a SMD of -2.72 (95% CI: -3.02, -2.43) in the 40-49 years age group and a SMD of -0.96 (95% CI: -1.73, -0.19) in the 50-59 years age group. The effect of high-dose atorvastatin therapy in reducing the serum creatinine levels, compared to low-dose therapy, was a SMD of -0.54 (95% CI: -1.03, -0.04). However, estimates for the effect of atorvastatin compared to rosuvastatin and placebo showed a SMD of -0.26 (95% CI: -0.76, 0.24) and -1.23 (95% CI: -2.22, -0.25), respectively. The effect of atorvastatin on blood urea nitrogen (BUN) and high-sensitivity C-reactive protein (hs-CRP) levels relative to the comparison group was a SMD of -1.10 (95% CI: -1.61, -0.58) and -1.36 (95% CI: -2.30, -0.42) respectively. Conclusion: Pre-treatment with atorvastatin is effective in CI-AKI prevention. High-dose atorvastatin administration at younger ages provides the best outcome for preventing CI-AKI. Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023397276, available at https:// www.crd.york.ac.uk/prospero/#recordDetails).
- 10 April 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
Open AccessThe effects of atorvastatin on contrast-induced acute kidney injury; a systematic review and meta-analysis on clinical trials
Introduction: Contrast-induced acute kidney injury (CI-AKI) is a major acute renal failure that can be prevented by atorvastatin administration. This study aims to evaluate the association between atorvastatin use and CI-AKI incidence using a systematic review and meta-analysis approach. Materials and Methods: Several international databases, including Cochrane, Web of Science, Scopus, ProQuest, PubMed, and the Google Scholar search engine, were queried in this study. STATA 14 software was conducted to analyze the data. In this study, standardized mean difference (SMD) index was conducted to investigate the relationship between atorvastatin and serum creatinine level. Results: Twelve clinical trials with a total sample size of 3299 were retrieved. The effect of atorvastatin on serum creatinine levels indicated a SMD of -2.26 (95% CI: -2.53, -1.98) at a dose of 20 mg/kg, -0.76 (95% CI: -1.47, -0.05) at a dose of 40 mg/kg, -2.69 (95% CI: -2.96, -2.42) at a dose of 60 mg/ kg, and -0.03 (95% CI: -0.14, 0.09) at a dose of 80 mg/kg. The effect of atorvastatin use on serum creatinine levels achieved a SMD of -2.72 (95% CI: -3.02, -2.43) in the 40-49 years age group and a SMD of -0.96 (95% CI: -1.73, -0.19) in the 50-59 years age group. The effect of high-dose atorvastatin therapy in reducing the serum creatinine levels, compared to low-dose therapy, was a SMD of -0.54 (95% CI: -1.03, -0.04). However, estimates for the effect of atorvastatin compared to rosuvastatin and placebo showed a SMD of -0.26 (95% CI: -0.76, 0.24) and -1.23 (95% CI: -2.22, -0.25), respectively. The effect of atorvastatin on blood urea nitrogen (BUN) and high-sensitivity C-reactive protein (hs-CRP) levels relative to the comparison group was a SMD of -1.10 (95% CI: -1.61, -0.58) and -1.36 (95% CI: -2.30, -0.42) respectively. Conclusion: Pre-treatment with atorvastatin is effective in CI-AKI prevention. High-dose atorvastatin administration at younger ages provides the best outcome for preventing CI-AKI. Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023397276, available at https:// www.crd.york.ac.uk/prospero/#recordDetails).